Brimapitide

Drug Profile

Brimapitide

Alternative Names: AM-111; AM111 peptide; D-JNKI-1; XG-102; XG102 peptide

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Xigen
  • Developer Auris Medical; ribOvax Biotechnologies; Xigen
  • Class Cardiovascular therapies; Eye disorder therapies; Neuroprotectants; Peptides
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ocular inflammation; Sensorineural hearing loss
  • Phase I Stroke
  • Preclinical Alzheimer's disease; Interstitial cystitis; Kidney disorders
  • No development reported Eye disorders
  • Discontinued Ear disorders; Myocardial infarction; Parkinson's disease; Transplant rejection

Most Recent Events

  • 21 Jun 2017 Discontinued - Preclinical for Myocardial infarction in Switzerland before June 2017, as the product is not listed in the pipeline for the indication (Xigen pipeline, June 2017)
  • 21 Jun 2017 Discontinued - Preclinical for Parkinson's disease in Switzerland before June 2017, as the product is not listed in the pipeline for the indication (Xigen pipeline, June 2017)
  • 21 Jun 2017 Discontinued - Preclinical for Transplant rejection in Switzerland before June 2017, as the product is not listed in the pipeline for the indication (Xigen pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top